secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001140361-25-000711
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Insmed reports preliminary 2024 ARIKAYCE revenue of $363.7M, sets 2025 guidance of $405-425M
--------------------------------------------------------------------------------

- Preliminary 2024 ARIKAYCE global net sales of $363.7M, up 19% YoY; 2025 guidance $405-425M (11-17% growth)
- Brensocatib NDA for bronchiectasis submitted to FDA in Dec 2024; U.S. launch expected Q3 2025 under priority review
- Phase 2 TPIP in PAH fully enrolled (102 patients); topline data now expected mid-2025
- ENCORE trial for ARIKAYCE in MAC lung disease enrolled 425 patients (exceeding 400 target); topline Q1 2026
- IND cleared for DMD gene therapy INS1201; first patient dosing anticipated H1 2025

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/0001140361-25-000711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer